Online Master's in Biomedical Engineering @ Case.edu
A Mighty Force - read full story

In The News

For all the promise of AI-created precision medicines, observers say there’s a long way to go before they'll come to a drugstore near you. Anant Madabhushi, a biomedical engineering professor at Case Western Reserve University School of Medicine, said, "there is a lot of optimism but also a lot of hype" in the use of AI for precision medicine.

The Research Highlights collection showcases the breadth of work being done by primary investigators with the support of grants from the EGRP portfolio. 

Inspirata: Upcoming fireside chat on Digital Pathology Innovation, being held virtually on March 2nd, featuring The Pathologist’s 2020 Power List, including Case Western Reserve University's 
Anant Madabhushi.

These hybrid nanoparticle systems can be intravenously administered to enable targeted hemorrhage control in treating traumatic injuries, and can act as platelet surrogates when platelet products are unavailable for transfusion. 

In an article titled, “Case Researchers Studying AI Use In Targeting Cancer Treatment,” author Anna Huntsman interviews CCIPD Director, Anant Madabhushi, PhD, about his work in precision medicine and recently-launched research agreement with the pharmaceutical company Boehringer Ingelheim. This collaboration will explore uses of AI to better identify therapies that are more likely to work for a specific patient. 

In a January 6th interview with Bio Patrika, Rakesh Shiradkar, PhD, discusses his vision, goals, and current projects with the Center for Computational Imaging and Personalized Diagnostics. Shiradkar further discusses the impact the center’s research is having on society and what personalized diagnostics means to him.

In a December 10th Reuters Health press release appearing on Medscape titled, “MRI-Based Nomograms May Predict Lymph Node Metastasis, Survival in Early Breast Cancer," author Marilynn Larkin quotes Nathaniel Braman, PhD, CCIPD alumnus, regarding how a machine learning MRI radiomic signature tool could help guide clinicians’ treatment decisions.

Newswise — CLEVELAND, Ohio --Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict how likely the disease is to recur following surgical treatment for prostate cancer. 

Anant Madabhushi, PhD, discusses how AI can be used to efficiently allocate healthcare resources by predicting response to treatment for COVID-19 patients.

Case Western Reserve and partners local and global team up to better predict which patients with oral squamous cell carcinomas will need radiation or chemotherapy after surgery

The agreement is the third partnership in 2020 between the CCIPD and leading biopharmaceutical companies to advance artificial intelligence (AI) tools for disease diagnosis and prognosis, as well as predicting response to therapy. In April, the CCIPD entered into a contract with AstraZeneca and earlier in the year had inked a similar deal with Bristol-Myers Squibb Company.

Researchers used AI to discover that coronavirus vaccines could be less effective for specific populations.

“Quality control for digital pathology slides” and “Vascular network organization via Hough transform (VaNgOGH): a radiomic biomarker for diagnosis and treatment response”. Congratulations to Anant Madabhushi, PhD, Donnell Institute Professor, biomedical engineering and Director of CCIPD; Andrew Janowczyk, PhD, research assistant professor, biomedical engineering and CCIPD, and alumni of CCIPD Nathaniel Braman, PhD and Prateek Prasanna, PhD.

“This idea [studying eye vasculature] is getting a variety of curiosity proper now,” Anant Madabhushi, PhD

Case Western Reserve University biomedical engineering leaders Scott Bruder, Anant Madabhushi honored for ‘spirit of innovation’

Radiomics analysis suggests underlying subvisual features may encode information related to tolerance of interval extension in retinal vascular disease

CCIPD’s Anant Madabhushi, PhD, and Pranjal Vaidya with collaborators Kaustav Bera, MD, and Vamsidhar Velcheti, MD, have been awarded US Patent #10,839,513, “Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features.” 

Eight CCIPD abstracts will be presented during the United States and Canadian Academy of Pathology (USCAP) 110th Virtual Annual Meeting, held on March 13-18th, 2021. 

Case Western Reserve University (CWRU) invites applications for a mid-level faculty position in the area of artificial intelligence and medical imaging.